Achilles Therapeutics AGM Concludes with Key Approvals

Achilles Therapeutics (ACHL) has released an update.

Achilles Therapeutics plc successfully held its Annual General Meeting in June 2024, with all proposed resolutions passed, including the re-election of its board members and the re-appointment of KPMG LLP as auditors. Shareholders also approved the company’s financial statements for the previous year but noted that no dividend will be paid for 2023. The details of these resolutions were previously provided to shareholders and filed with the U.S. SEC in May 2024.

For further insights into ACHL stock, check out TipRanks’ Stock Analysis page.